From : nmamaladze@moh.gov.ge
To : Sonia Choi <Sonia.Choi@gilead.com>
Subject : Re: Fwd: Gilead Georgia Backgrounder
Received On : 20.04.2015 20:35

Thank you Sonia, This information will be taken into consideration for tomorrow event. Yours faithfully, Nino -----Original Message----- From: Sonia Choi To: nino mamaladze Date: Mon, 20 Apr 2015 19:47:53 +0100 Subject: Fwd: Gilead Georgia Backgrounder > Dear Nino - attached is the updated press release to which I referred > in my previous email. > > Many thanks, > Sonia > > Begin forwarded message: > > From: Sonia Choi > > Date: April 19, 2015 at 9:42:41 PM GMT+4 > To: "Averhoff, Francisco (CDC/OID/NCHHSTP)" > >, Graeme Robertson > >, > "Morgan, Juliette (CDC/CGH/DGHP)" >, > "'dsergeenko@moh.gov.ge'" > >, > "'346234@gmail.com'" > <346234@gmail.com>, > "'vkvaratskhelia@moh.gov.ge'" > > > Cc: Enrico Magnanelli > >, > Gregg Alton > > Subject: RE: Gilead Georgia Backgrounder > > Thank you, Francisco. > > Dear Minister – please find attached an updated draft press release > for your consideration that incorporates Francisco’s suggested > changes. The main changes were the inclusion of detail on phases 1 and > 2 and the addition of a quote from John Ward. > > Best wishes, > Sonia > > > From: Averhoff, Francisco (CDC/OID/NCHHSTP) [mailto:fma0@cdc.gov] > Sent: 19 April 2015 12:03 > To: Sonia Choi; Graeme Robertson; Morgan, Juliette (CDC/CGH/DGHP); > 'dsergeenko@moh.gov.ge'; > '346234@gmail.com'; > 'vkvaratskhelia@moh.gov.ge' > Cc: Enrico Magnanelli > Subject: Re: Gilead Georgia Backgrounder > > Dear Sonia, > > > I think it is necessary to emphasize from original TPs that this Phase > I is a compassionate use/early intervention targeting those with more > advanced liver disease, at risk of morbidity/mortality, as part of > greater elimination program. I will send suggested revisions. Thx, FA > > From: Sonia Choi [mailto:Sonia.Choi@gilead.com] > Sent: Friday, April 17, 2015 10:37 PM > To: Graeme Robertson > >; > Morgan, Juliette (CDC/CGH/DGHP); Averhoff, Francisco (CDC/OID/NCHHSTP); > David Sergeenko >; > David Chitaia <346234@gmail.com>; valeri > (vkvaratskhelia@moh.gov.ge) > > > Cc: Enrico Magnanelli > > > Subject: RE: Gilead Georgia Backgrounder > > Dear all – > > Attached please find the latest draft press release. We have included a > quote from Gilead and there is a placeholder for a quote from CDC. > > Many thanks, > Sonia > > From: Graeme Robertson > Sent: 17 April 2015 20:06 > To: Morgan, Juliette (CDC/CGH/DGHP); Averhoff, Francisco > (CDC/OID/NCHHSTP); David Sergeenko; David Chitaia; valeri > (vkvaratskhelia@moh.gov.ge) > Cc: Sonia Choi; Enrico Magnanelli > Subject: Gilead Georgia Backgrounder > > Dear All, > > Please see attached backgrounder that we have developed utilising what > Francisco had provided. > > Best wishes > > Graeme > > Graeme Robertson > Director > Access Operations & Emerging Markets > DISCLAIMER If you have received this message in error, please contact > the sender immediately by return e-mail and notify the sender and then > delete this message (including any attachments) from your system. This > communication and any attachments contain information which is > confidential and may also be legally privileged. It is for the > exclusive use of the intended recipient(s). If you are not the intended > recipient(s) please note that any form of disclosure, distribution, > copying or use of this communication or the information in it or in any > attachments is strictly prohibited and may be unlawful. E-mail > communications cannot be guaranteed to be secure or error free, as > information could be intercepted, corrupted, amended, lost, destroyed, > arrive late or incomplete, or contain viruses. Gilead does not accept > liability for any such matters or their consequences. Anyone who > communicates with Gilead by e-mail is taken to accept the risks in > doing so. Gilead has taken every reasonable precaution to ensure that > any attachment to this e-mail has been swept for viruses. However, > Gilead cannot accept liability for any damage sustained as a result of > viruses and would advise that you carry out your own virus checks > before opening any attachment. Gilead Sciences Europe Ltd ; Registered > as a limited company in England and Wales ; Registered number 5510315 > Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park > ; Uxbridge ; UB11 1AF ; England